Skip to main content
Top
Published in: Annals of Surgical Oncology 12/2018

01-11-2018 | Gynecologic Oncology

Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma

Authors: Koji Matsuo, Yutaka Takazawa, Malcolm S. Ross, Esther Elishaev, Mayu Yunokawa, Todd B. Sheridan, Stephen H. Bush, Merieme M. Klobocista, Erin A. Blake, Tadao Takano, Tsukasa Baba, Shinya Satoh, Masako Shida, Yuji Ikeda, Sosuke Adachi, Takuhei Yokoyama, Munetaka Takekuma, Shiori Yanai, Satoshi Takeuchi, Masato Nishimura, Keita Iwasaki, Marian S. Johnson, Masayuki Yoshida, Ardeshir Hakam, Hiroko Machida, Paulette Mhawech-Fauceglia, Yutaka Ueda, Kiyoshi Yoshino, Hiroshi Kajiwara, Kosei Hasegawa, Masanori Yasuda, Takahito M. Miyake, Takuya Moriya, Yoshiaki Yuba, Terry Morgan, Tomoyuki Fukagawa, Tanja Pejovic, Tadayoshi Nagano, Takeshi Sasaki, Abby M. Richmond, Miriam D. Post, Mian M. K. Shahzad, Dwight D. Im, Hiroshi Yoshida, Takayuki Enomoto, Kohei Omatsu, Frederick R. Ueland, Joseph L. Kelley, Rouzan G. Karabakhtsian, Lynda D. Roman

Published in: Annals of Surgical Oncology | Issue 12/2018

Login to get access

Abstract

Purpose

To propose a categorization model of uterine carcinosarcoma (UCS) based on tumor cell types (carcinoma and sarcoma) and sarcoma dominance.

Methods

This secondary analysis of a prior multicenter retrospective study examined 889 cases of UCS with available histologic evaluation. Based on survival outcome, cases were clustered into three groups: low-grade carcinoma with nondominant homologous sarcoma [type A, n = 96 (10.8%)], (1) low-grade carcinoma with heterologous sarcoma or any sarcoma dominance and (2) high-grade carcinoma with nondominant homologous sarcoma [type B, n = 412 (46.3%)], and high-grade carcinoma with heterologous sarcoma or any sarcoma dominance [type C, n = 381 (42.9%)]. Tumor characteristics and outcome were examined based on the categorization.

Results

Women in type C category were more likely to be older, obese, and Caucasian, whereas those in type A category were younger, less obese, Asian, and nulligravid (all P < 0.01). Type C tumors were more likely to have metastatic implants, large tumor size, lymphovascular space invasion with sarcoma cells, and higher lymph node ratio, whereas type A tumors were more likely to be early-stage disease and small (all P < 0.05). On multivariate analysis, tumor categorization was independently associated with progression-free survival (5-year rates: 70.1% for type A, 48.3% for type B, and 35.9% for type C, adjusted P < 0.01) and cause-specific survival (5-year rates: 82.8% for type A, 63.0% for type B, and 47.1% for type C, adjusted P < 0.01).

Conclusion

Characteristic differences in clinicopathological factors and outcomes in UCS imply that different underlying etiologies and biological behaviors may be present, supporting a new classification system.
Appendix
Available only for authorised users
Literature
3.
go back to reference Zhao S, Bellone S, Lopez S, et al. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. Proc Natl Acad Sci U S A. 2016;113:12238–43.CrossRefPubMedPubMedCentral Zhao S, Bellone S, Lopez S, et al. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. Proc Natl Acad Sci U S A. 2016;113:12238–43.CrossRefPubMedPubMedCentral
4.
go back to reference Matsuo K, Takazawa Y, Ross MS, et al. Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma. Ann Oncol. 2016;27:1257–66.CrossRefPubMed Matsuo K, Takazawa Y, Ross MS, et al. Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma. Ann Oncol. 2016;27:1257–66.CrossRefPubMed
5.
go back to reference Matsuo K, Takazawa Y, Ross MS, et al. Characterizing sarcoma dominance pattern in uterine carcinosarcoma: homologous versus heterologous element. Surg Oncol. 2018;27:433–40.CrossRefPubMedPubMedCentral Matsuo K, Takazawa Y, Ross MS, et al. Characterizing sarcoma dominance pattern in uterine carcinosarcoma: homologous versus heterologous element. Surg Oncol. 2018;27:433–40.CrossRefPubMedPubMedCentral
6.
go back to reference Matsuo K, Omatsu K, Ross MS, et al. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. Gynecol Oncol. 2017;145:78–87.CrossRefPubMedPubMedCentral Matsuo K, Omatsu K, Ross MS, et al. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. Gynecol Oncol. 2017;145:78–87.CrossRefPubMedPubMedCentral
7.
go back to reference Matsuo K, Ross MS, Bush SH, et al. Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma. Gynecol Oncol. 2017;144:329–35.CrossRefPubMed Matsuo K, Ross MS, Bush SH, et al. Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma. Gynecol Oncol. 2017;144:329–35.CrossRefPubMed
8.
go back to reference Matsuo K, Johnson MS, Im DD, et al. Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery. J Surg Oncol. 2017;117:488–96.CrossRefPubMedPubMedCentral Matsuo K, Johnson MS, Im DD, et al. Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery. J Surg Oncol. 2017;117:488–96.CrossRefPubMedPubMedCentral
9.
go back to reference Matsuo K, Ross MS, Im DD, et al. Significance of venous thromboembolism in women with uterine carcinosarcoma. Gynecol Oncol. 2018;148:267–74.CrossRefPubMed Matsuo K, Ross MS, Im DD, et al. Significance of venous thromboembolism in women with uterine carcinosarcoma. Gynecol Oncol. 2018;148:267–74.CrossRefPubMed
10.
go back to reference Matsuo K, Ross MS, Yunokawa M, et al. Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma. Gynecol Oncol. 2018;147:565–71.CrossRef Matsuo K, Ross MS, Yunokawa M, et al. Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma. Gynecol Oncol. 2018;147:565–71.CrossRef
11.
go back to reference Matsuo K, Takazawa Y, Ross MS, et al. Significance of lympho-vascular space invasion by sarcomatous component in uterine carcinosarcoma. Ann Surg Oncol. 2018;25:2756–66.CrossRefPubMedPubMedCentral Matsuo K, Takazawa Y, Ross MS, et al. Significance of lympho-vascular space invasion by sarcomatous component in uterine carcinosarcoma. Ann Surg Oncol. 2018;25:2756–66.CrossRefPubMedPubMedCentral
12.
go back to reference Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomised studies. Eur J Cancer. 2010;46:2422–31.CrossRefPubMedPubMedCentral Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomised studies. Eur J Cancer. 2010;46:2422–31.CrossRefPubMedPubMedCentral
13.
go back to reference de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:295–09.CrossRefPubMedPubMedCentral de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:295–09.CrossRefPubMedPubMedCentral
15.
go back to reference von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806–8.CrossRef von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806–8.CrossRef
16.
go back to reference Sampath S, Gaffney DK. Role of radiotherapy treatment of uterine sarcoma. Best Pract Res Clin Obstet Gynaecol. 2011;25:761–72.CrossRefPubMed Sampath S, Gaffney DK. Role of radiotherapy treatment of uterine sarcoma. Best Pract Res Clin Obstet Gynaecol. 2011;25:761–72.CrossRefPubMed
17.
go back to reference Rauh-Hain JA, Starbuck KD, Meyer LA, et al. Patterns of care, predictors and outcomes of chemotherapy for uterine carcinosarcoma: a National Cancer Database analysis. Gynecol Oncol. 2015;139:84–9.CrossRefPubMed Rauh-Hain JA, Starbuck KD, Meyer LA, et al. Patterns of care, predictors and outcomes of chemotherapy for uterine carcinosarcoma: a National Cancer Database analysis. Gynecol Oncol. 2015;139:84–9.CrossRefPubMed
18.
go back to reference Manzerova J, Sison CP, Gupta D, et al. Adjuvant radiation therapy in uterine carcinosarcoma: a population-based analysis of patient demographic and clinical characteristics, patterns of care and outcomes. Gynecol Oncol. 2016;141:225–30.CrossRefPubMed Manzerova J, Sison CP, Gupta D, et al. Adjuvant radiation therapy in uterine carcinosarcoma: a population-based analysis of patient demographic and clinical characteristics, patterns of care and outcomes. Gynecol Oncol. 2016;141:225–30.CrossRefPubMed
19.
go back to reference Seagle BL, Kanis M, Kocherginsky M, Strauss JB, Shahabi S. Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy. Gynecol Oncol. 2017;145:71–7.CrossRefPubMed Seagle BL, Kanis M, Kocherginsky M, Strauss JB, Shahabi S. Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy. Gynecol Oncol. 2017;145:71–7.CrossRefPubMed
20.
go back to reference Voss MA, Ganesan R, Ludeman L, McCarthy K, Gornall R, Schaller G, Wei W, Sundar S. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation. Gynecol Oncol. 2012;124:15–20.CrossRefPubMed Voss MA, Ganesan R, Ludeman L, McCarthy K, Gornall R, Schaller G, Wei W, Sundar S. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation. Gynecol Oncol. 2012;124:15–20.CrossRefPubMed
21.
go back to reference Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67–73.CrossRefPubMed Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67–73.CrossRefPubMed
Metadata
Title
Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma
Authors
Koji Matsuo
Yutaka Takazawa
Malcolm S. Ross
Esther Elishaev
Mayu Yunokawa
Todd B. Sheridan
Stephen H. Bush
Merieme M. Klobocista
Erin A. Blake
Tadao Takano
Tsukasa Baba
Shinya Satoh
Masako Shida
Yuji Ikeda
Sosuke Adachi
Takuhei Yokoyama
Munetaka Takekuma
Shiori Yanai
Satoshi Takeuchi
Masato Nishimura
Keita Iwasaki
Marian S. Johnson
Masayuki Yoshida
Ardeshir Hakam
Hiroko Machida
Paulette Mhawech-Fauceglia
Yutaka Ueda
Kiyoshi Yoshino
Hiroshi Kajiwara
Kosei Hasegawa
Masanori Yasuda
Takahito M. Miyake
Takuya Moriya
Yoshiaki Yuba
Terry Morgan
Tomoyuki Fukagawa
Tanja Pejovic
Tadayoshi Nagano
Takeshi Sasaki
Abby M. Richmond
Miriam D. Post
Mian M. K. Shahzad
Dwight D. Im
Hiroshi Yoshida
Takayuki Enomoto
Kohei Omatsu
Frederick R. Ueland
Joseph L. Kelley
Rouzan G. Karabakhtsian
Lynda D. Roman
Publication date
01-11-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 12/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6695-z

Other articles of this Issue 12/2018

Annals of Surgical Oncology 12/2018 Go to the issue